Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the ...

Separately, a Delaware jury in late October found that Masimo’s current products did not infringe any of Apple’s patents. The ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Young said Masimo is lowering corporate overhead costs, with cuts such as selling the corporate jet and reducing marketing expenses for products that aren't producing meaningful revenue and returns.

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. EPS ...

4 analysts have expressed a variety of opinions on Masimo MASI over the past quarter ... remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...